CR Double-Crane(SH:600062)2022-04-28 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 2,518,174,975.92, representing a 4.59% increase year-over-year[6]. - Net profit attributable to shareholders was CNY 331,971,014.87, reflecting a 15.99% increase compared to the same period last year[6]. - The net profit after deducting non-recurring gains and losses was CNY 317,717,474.58, up by 19.48% year-over-year[6]. - Basic and diluted earnings per share were both CNY 0.3182, marking a 15.99% increase[6]. - Operating profit for Q1 2022 was ¥424,020,624.79, up 18.3% from ¥358,500,072.98 in Q1 2021[20]. - Net profit for Q1 2022 was ¥345,356,206.23, representing a 16.2% increase from ¥297,164,529.40 in Q1 2021[21]. - Total comprehensive income for Q1 2022 was ¥345,355,685.67, an increase from ¥297,164,492.56 in Q1 2021[21]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 44.34%, amounting to CNY 179,637,208.19, primarily due to a reduction in the balance of receivables[6][8]. - Cash flow from operating activities for Q1 2022 was ¥179,637,208.19, a decrease of 44.2% compared to ¥322,732,752.17 in Q1 2021[22]. - Cash inflow from operating activities totaled ¥2,245,590,205.14 in Q1 2022, down from ¥2,399,083,493.29 in Q1 2021[22]. - Cash outflow from operating activities was ¥2,065,952,996.95 in Q1 2022, compared to ¥2,076,350,741.12 in Q1 2021[22]. - The cash and cash equivalents decreased to CNY 2,713,587,721.04 from CNY 2,834,035,295.68, representing a decline of about 4.26%[16]. - The cash and cash equivalents at the end of Q1 2022 amounted to approximately ¥1.77 billion, slightly up from ¥1.72 billion at the end of Q1 2021[23]. - The cash and cash equivalents decreased by approximately ¥118.01 million in Q1 2022, contrasting with an increase of ¥230.81 million in Q1 2021[23]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,713,457,608.57, a slight increase of 0.27% from the end of the previous year[6]. - The total liabilities of the company as of March 31, 2022, were CNY 3,177,908,131.69, slightly down from CNY 3,199,498,957.85, a decrease of approximately 0.67%[18]. - The company's equity attributable to shareholders increased to CNY 9,956,373,840.47 from CNY 9,905,495,654.72, reflecting a growth of about 0.52%[18]. - Accounts receivable increased significantly to CNY 1,496,814,196.36, up from CNY 1,232,982,001.21, marking an increase of approximately 21.43%[16]. - Inventory levels decreased to CNY 1,555,242,234.23 from CNY 1,665,455,865.49, indicating a reduction of about 6.61%[16]. - The company's fixed assets decreased to CNY 2,616,211,709.99 from CNY 2,629,698,915.82, a decline of approximately 0.52%[17]. Investments and Financial Management - The total amount of entrusted financial management reached 1,450,000,000.00 CNY during the reporting period[14]. - The company reported an actual return of 4,090,890.41 CNY from its entrusted financial management activities[14]. - The annualized yield rates for various entrusted financial products ranged from 1.3% to 3.48%[13]. - The company has plans for future entrusted financial management, indicating ongoing investment strategies[14]. - The expected returns from entrusted financial management were linked to derivative market performance[13]. - The company’s financial products included structured deposits linked to financial derivatives, enhancing potential returns[14]. Shareholder Information - The top shareholder, Beijing Pharmaceutical Group Co., Ltd., holds 625,795,624 shares, accounting for 59.99% of the total shares[9]. - The company reported a total of 42,810 common shareholders at the end of the reporting period[9]. Management and Governance - The company did not apply the new accounting standards for the first time in 2022, which may impact future financial reporting[23]. - The company’s management team includes key personnel such as Feng Yi and Fan Yanxi, responsible for accounting and financial oversight[23].